Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults over 18 years of age.

COVID-19 2024–2025 vaccines are recommended for everyone aged 6 months and older, with vaccines targeting the JN.1 and KP.2 strains of SARS-CoV-2.

PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the third quarter.

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...

Researchers evaluated protection conferred by a single COVID-19 mRNA vaccine dose vs a 2-dose series in the setting of high preexisting SARS-CoV-2 immunity.

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.

The first day of flu and COVID shots set a single-day record, with 82,000 shots administered through B.C. pharmacies ...

Me CEO Anne Wojcicki continues to maintain a strong outlook despite recent high-profile stumbles. “We are a long-term company ...

Sniff spikes, the study noted, might help researchers better understand some of the mental issues experienced by covid patients who have lost their sense of smell. Separately, researchers found that ...

For anyone without insurance, you can find a free flu shot provider under the state Department of Health Services Vaccines ...

Its cheap valuation, strong growth prospects, and massive dividend make it ripe for outsize investment returns.